Top 50 Biotech Firms — Great Bay Bio, EngeneBio, and Akeso Announce Major Milestones

"Top 50 Enterprises News"

Top 50 Biotech Innovation Pioneering Enterprises of the 7th Edition – Great Bay Bio (hereinafter referred to as "Great Bay Bio") announced the completion of the first phase of its Series B financing.This round of financing was led by a well-known industrial investment institution and its affiliated Taixin Capital Beibao Accelerator, with participation from Hong Kong Science and Technology Park Venture Fund and Hong Kong family offices, as well as continued investment from global biotechnology industry players. The funds raised will be used for the research and development of GBB's intelligent drug development ecosystem technology platform and to further expand Great Bay Bio's market influence in global biopharmaceutical development. This also marks a new milestone for GBB in promoting biopharmaceutical development on an international scale.

Great Bay Bio is a biotechnology company that drives drug development through cutting-edge technologies such as artificial intelligence, big data mining, and automation.The core team is composed of experts from various fields such as medicine, synthetic biology, and artificial intelligence both in China and overseas. It has a 3,000-square-meter R&D laboratory base and CMC platform, which has helped clients obtain the approval of the National Medical Products Administration (NMPA) of China and the Investigational New Drug (IND) tacit permission from the U.S. Food and Drug Administration (FDA). Over the years since its establishment, Great Bay Bio has applied for nearly a hundred patents in AI-driven drug development and successfully commercialized multiple AI technology platforms, establishing long-term cooperation with several top enterprises both domestically and internationally.

Recently,Akeso's globally pioneering PD-1/VEGF bispecific antibody new drug, Efvorsi, which was independently developed by Akeso, one of the top 50 biotech innovation companies in the first selection, has been included in the "Most Valuable R&D Projects" list due to its outstanding innovative value and market potential., making it the only drug on the list independently developed by an innovative Chinese pharmaceutical company.

Ewoxi is a bispecific antibody drug independently developed by Akeso, marking the world's first dual-targeting anti-tumor mechanism that combines "tumor immunotherapy + anti-angiogenesis." The drug can simultaneously target two blockbuster-level key targets, PD-1 and VEGF, leveraging both tumor immunity and anti-angiogenesis mechanisms in synergy. Clinical studies have demonstrated that Ewoxi exhibits excellent clinical efficacy.EVOICITINIB Approved by NMPA in May 2024 for EGFR-TKI-treated locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC). The Phase III clinical trial (HARMONi-A) for this indication demonstrated that EVOICITINIB combination therapy achieved a record-breaking 54% reduction in the risk of disease progression or death, with a clear trend toward long-term survival benefits. This addresses the unmet clinical need for third-generation EGFR-TKI resistance in non-small cell lung cancer patients in China. Currently, EVOICITINIB for this indication has been included in the 2024 National Reimbursement Drug List.